Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Whey Protein wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
26 of 30 studies with measurable effects showed benefit.
Top outcomes
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
20-40g per serving
Post-workout (within 2 hours), Morning, Between meals
Whey Protein Isolate
Progressive over 24-46 weeks
By 48 weeks
By 16-46 weeks
Especially during dose escalation
4-8 weeks
24-48 hours post-workout
Immediate
Within hours of consumption
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med (2024) · Rct · n=293
48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Diabetes Endocrinol (2024) · Rct · n=387
Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia (2024) · Rct · n=413
Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm
Comparative Efficacy of Different Protein Supplements on Muscle Mass, Strength, and Physical Indices of Sarcopenia among Community-Dwelling, Hospitalized or Institutionalized Older Adults Undergoing Resistance Training: A Network Meta-Analysis of Randomized Controlled Trials
Nutrients (2024) · Meta analysis · n=5272
Treatment effects for main outcomes were expressed as standard mean difference (SMD) with 95% confidence interval (CI).
Effects of Whey Protein, Leucine, and Vitamin D Supplementation in Patients with Sarcopenia: A Systematic Review and Meta-Analysis
Nutrients (2023) · Meta analysis · n=637
However, appendicular muscle mass significantly improved in the experimental group compared to the control group.
A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength
British Journal of Sports Medicine (2018) · Meta analysis · n=1863
Protein supplementation increases muscle mass gains
Based on multiple meta-analyses with >3000 participants. Effects require concurrent resistance training. Benefits plateau around 30-40g per serving. Isolate forms may reduce digestive issues.
AI-estimated from published studies. Interpret as directional guidance.
Whey Protein has a higher evidence score (9/10 vs 5.5/10) and wins in 3 of 3 categories.
No known interactions between Survodutide and Whey Protein have been documented in our database. However, always consult a healthcare provider before combining supplements.